Abstract
Erythropoietin (EPO) is a 30.4 kDa glycoprotein hormone secreted by the kidneys in response to tissue hypoxia, which stimulates red blood cell production. To regulate erythrocyte production, recombinant human EPO (rHuEPO) activates the EPO receptor (EPOR) and stimulates the proliferation and differentiation of erythrocytic progenitors in the bone marrow, leading to reticulocytosis and increased erythrocyte numbers and hemoglobin concentration in the blood. Epoetin alfa, the first commercial form of rHuEPO marketed in the United States of America (USA) and European Union (EU), and epoetin beta marketed outside the USA are both expressed in Chinese hamster ovary (CHO) cells. Both epoetins have a 165-amino acid sequence identical to human urinary EPO, contain three sialic acid-containing N-linked and one O-linked carbohydrate chains [1] leading to the same biologic effects as endogenous EPO [2–4]. No important differences in clinical efficacy are apparent between epoetin alfa and epoetin beta, and they are generally used interchangeably [5]. Darbepoetin alfa is a hyperglycosylated rHuEPO analog with five amino acid changes and two additional N-linked carbohydrate chains, which has the same mechanism of action as rHuEPO. Darbepoetin alfa, however, has a three-fold increased serum half-life [6–8], and increased in vivo potency [9], allowing for more convenient modes of administration, including extended dosing intervals [10, 11].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Halstenson CE, Macres M, Katz SA et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702–712.
Egrie JC, Strickland TW, Lane J et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986;72:213–224.
Imai N, Kawamura A, Higuchi M et al. Physiocochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem 1990;107:352–359.
Rency MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 1987;262:17156–17163.
Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharmaceut Biotechnol 2000;1:11–31.
Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392–2395.
Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414–421.
Sinclair AM, Elliott S. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 2005;94:1626–1635.
Egrie JC, Dwyer E, Browne JK et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290–299.
Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110–118.
Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211–1220.
Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesisstimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436–440.
Erslev AJ. In vitro production of erythropoietin by kidneys perfused with a serum-free solution. Blood 1974;44:77–85.
Syed RS, Reid SW, Li C et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998;395:511–516.
Elliott S, Lorenzini T, Chang D et al. Mapping of the active site of recombinant human erythropoietin. Blood 1997;8:493–502.
Youssoufian H, Longmore G, Neumann D et al. Structure, function, and activation of the erythropoietin receptor. Blood 1993;81:2223–2236.
Fraser JK, Lin FK, Berridge MV. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. Exp Hematol 1988;16:836–842.
Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 1987;262:5554–5562.
Matthews DJ, Topping RS, Cass RT et al. A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci USA 1996;93:9471–9476.
Philo JS, Aoki KH, Arakawa T et al. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 1996;35:1681–1691.
Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood 1989;74:103–109.
Walrafen P, Verdier F, Kadri Z et al. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005;105:600–608.
Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006;281:2024–2032.
Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992;72:449–489.
Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1–14.
Koury MJ, Bondurant MC. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol 1988;137:65–74.
Gregoli PA, Bondurant MC. The roles of Bcl-XL and apopain in the control of erythropoiesis by erythropoietin. Blood 1997;89:630–640.
Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002;22:503–514.
Sawyer T, Jacobs-Helber SM. Unraveling distinct intracellular signals that promote survival and proliferation: study of erythropoietin, stem cell factor, and constitutive signaling in leukemic cells. J Hemather Stem Cell Res 2000;9:21–29.
Kashii Y, Uchida M, Kirito K et al. A member of Forkhead family transcription factors FKHRL, is one of the downstream molecules of phosphatidylinositol 3-kinase-AKT activation pathway in erythropoietin signal transduction. Blood 2000;96:941–949.
Ghaffari S, Jagani Z, Kitidis C et al. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 2003;100:6523–6528.
Zamai L, Secchiero P, Pierpaoli S et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000;95:3716–3724.
Jarsch M, Brandt M, Lanzendörfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63–69.
Canaud B, Mingardi G, Braun J et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008) Epub Jun 27.
Spivak JL. The biology and clinical applications of recombinant erythropoietin. Semin Oncol 1998;25:7–11.
Buemi M, Cavallaro E, Floccari F et al. The pleiotropic effect of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003;62:228–236.
Spivak JL. Changing paradigms in anemia management. Adv Studies Med 2002;22:610–619.
Besarab A. Physiological and pharmacodynamic considerations for route of EPO administration. Semin Nephrol 2000;20:364–374.
Soulliard A, Audran M, Bressolle F et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br J Clin Pharmacol 1996;42:355–364.
Koopman MG, Koomen GC, Krediet RT et al. Cireadian rhythm of glomerular filtration rate in normal individuals. Clin Sci 1989;77:105–111.
Wide L, Bengtsson C, Birgegard G. Circadian rhythm of erythropoietin in human serum. Br J Haematol 1989;72:85–90.
Pasqualetti P, Collacciani A, Casale R. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. Eur Rev Med Pharmacol Sci 2000;4:111–115.
Hayashi N, Kinoshita H, Yukawa E et al. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. Br J Clin Pharmacol 1998;46:11–19.
Olsson-Gisleskog P, Jacqmin P, Perez-Ruixo JJ. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet 2007;46:159–173.
Kendall RG. Erythropoietin. Clin Lab Haematol 2001;23:71–80.
Erslev AJ. Erythropoietin. N Engl J Med 1991;324:1339–1344.
Jungers PY, Robino C, Choukroun G et al. Incidence of anaemia, and use of Epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 2002;17:1621–1627.
Nissenson AR, Nimer SD, Wolcott DL. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med 1991; 114:402–416.
Adamson JW, Eschbach JW. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Ann Rev Med 1990;41:349–360.
Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998;13:23–27.
Kato A, Hishida A, Kumagai H et al. Erythropoietin production in patients with chronic renal failure. Ren Fail 1994;16:645–651.
Ross RP, McCrea JB, Besarab A. Erythropoiein response to blood loss in hemodialysis patients is blunted but preserved. ASAIO J 1994;40:M880–885.
Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–1692.
Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001;28:1–6.
Endo Y, Nagai H, Watanabe Y et al. Heat-induced aggregation of recombinant erythropoietin in the intact and deglycosylated states as monitored by gel permeation chromatography combined with a low-angle laser light scattering technique. J Biochem 1992;112:700–706.
Pedain C, Herrero J, Kunzel W. Serum erythropoietin levels in ovarian cancer patients receiving chemotherapy. Eur J Obstet Gynecol Reprod Biol 2001;98:224–230.
Glaspy J, Henry D, Patel R et al. The effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140–1149.
Schmalbach TK, Borch RF. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine (cyclobutanedicarboxylato) platinum (II). Cancer Res 1989; 49:6629–6633.
Boxenbaum H. Pharmacokinetic tricks and traps: flip-flop models. J Pharm Pharmaceut Sci 1998;1:90–91.
Varlet-Marie E, Gaudard A, Audran M et al. Pharmacokinetics-pharmacodynamics of recombinant human erythropoietins in doping control. Sport Med 2003;33:301–315.
Heatherington AC. Clinical pharmacokinetic properties of rHuEPO: a review. In: Molineux G, Foote MA, Elliott S, eds., Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology, Birkhauser, Basel, Switzerland, 2003; pp 87–112.
Cheung WK, Goon BI., Guilfoyle MC et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple, subcutaneous doses to healthy subject. Clin Pharmacol Ther 1998;64:412–423.
Markham A, Bryson HM. Epoetin alfa A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications Drug Eval 1995;49:232–254.
Jensen JD, Madsen JK, Jensen LW et al. Reduced production, absorption, and elimination of erythro poietin in uremia compared with healthy volunteers. J Am Soc Nephrol 1994;5:177–185
Sans T, Joven J, Vilella E et al. Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusions. Clin Exp Pharmacol Physiol 2000;27:179–184.
McMahon FG, Vargas R, Ryan M et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76:1718–1722.
Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharmacol Res 1990;7:167–169.
Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000;89:297–310.
McLennan DN, Porter CJ, Edwards GA et al. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharmacol Res 2003;20:1156–1162.
Leak LV. The structure of lymphatic capillaries in lymph formation. Fed Proc. 1976;35:1863–1871.
McLennan DN, Porter CJ, Edwards GA et al. Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther 2005;313:345–351.
McLennan DN, Porter CJ, Edwards GA et al. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. Pharmacol Res 2006;23:2060–2066.
Kagan L, Gershkovich P, Mendelman A et al. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm 2007;67:759–765.
Bendayan M. Morphological and cytochemical aspects of capillary permeability. Microsc Res Tech 2002;57:327–349.
Kota J, Machavaram KK, McLennan DN et al. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos 2007;35:2211–2217.
Woo S, Krzyzanski W, Jusko WJ. Pharmacolinetic and pharmacodynamic modeling human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 2006;319:1297–1306.
Ramakrishnan, R, Cheung WK, Farrell F et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 2003;306:324–331.
Krzyzanski W, Jusko WJ, Wacholtz MC et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 2005;26:295–306.
Glaspy J, Henry D, Patel R et al. The effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140–1149.
Agoram B, Sutjandra, L, Sullivan JT. Population pharmacokinetics, of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol 2007;63:41–52.
Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)protein conjugates. Adv Drug Deliv Rev 2003;55:1261–1277.
European Medicines Association. Scientific discussion: summary of product characteristics: MIRCERA (methoxy polyethyl-ene glycol-epoetin beta). Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/mircera/H-739-en6.pdf [Accessed 2008 May 20].
Fishbane S, Pannier A, Liogier X. et al. Pharmacokinetic and pharmacodynamic properties of methoxy-polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007;47:1390–1397.
Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 1994;46:333–337.
Macdougall IC, Jones JM, Robinson MI et al. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol 1991;88:152–156.
Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990;29:709–713.
Jensen JD, Madsen JK, Jensen LW et al. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 1994;5:177–185.
Deicher R, Horl WH. Differentiating factors between erythropoiesis stimulating agents: a guide to selection for anemia of chronic kidney disease. Drugs 2004;64:499–509.
Karlsson MO, Sheiner LB. Estimating bioavailability when clearance varies with time. Clin Pharmacol Ther 1994;55:623–637.
Elliot S, Heatherington AC, Foote MA Erythropoietic Factors: Clinical Pharmacology and Pharmacokinetics. In: Morstyn G, Foote M and Lieschke eds. Hematopoietic Growths Factors in Oncology Humana Press (NJ) pp 97–123.
Cheung WK, Goon BL, Guifoyle MC et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998;64:412–423.
Cheung WK, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001;57:411–418.
Ramakrishnan R, Cheung WK, Wacholtz MC et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004;44:991–1002.
Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987;48:591–596.
Macdougall IC, Roberts DE, Coles GA et al. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991;20:99–113.
Kampf D, Kahl A, Passlick J et al. Single-dose kinetics of recombinant human erythrooietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results. Contrib Nephrol 1989;76:106–111.
Bommer J, Barth HP, Zeier M et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991;88:136–143.
Flaharty KK, Caro J, Erslev A et al. Pharmacokinetics and erythropoietic nesponse to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990;47:557–564.
Braeckman R. Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Peptide and protein drug delivery. New York, Marcel Dekker, 1991;391–384.
Kompella A, Lee VHL. Pharmacokinetics of peptide and protein drugs. In: Peptides and protein drug analysis. Reid ER (editor) New York, Marcel Dekker, 2000; 633–669.
Uji Y, Hirashima K, Hirasawa Y et al. Recombinant erythropoietin Phase I clinical study-single intravenous administration. Med Consult N Rem 1989;26:1–28.
Uji Y, Hirashima K, Hirasawa Y et al. Recombinant erythropoietin Phase I clinical study-multiple intravenous administration. Med Consult N Rem 1989;26:29–44.
Woo S, Jusko WJ. Interspecies comparison of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin (rH-EPO). Drug Metab Dispos 2007;35:1672–1678.
Allon M, Kleinman K, Walczyk M et al. Pharmacokinetics and pharmacodynamics of darberpoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002;72:546–555.
Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001;84:11–16.
Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AA PS J 2006;8:E552–E563.
Brockmöller J, Kochling J, Weber W et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 1992;34:499–508.
Kindler J, Eckardt KU, Ehmer B et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989;4:345–349.
Neumayer HH, Brockmöller J, Fritschka E et al. Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis. Contrib Nephrol 1989; 76:131–141.
Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 1990;66:83–86.
Xenocostas A, Cheung WK, Farrell F et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005;61:189–195.
Farrel FX, Juul S, Elliot C et al. Erythropoietin crosses the blood-brain barrier: an analysis in a nonhuman primate model. Blood 2001;98:148b
Jumbe NL. Erythropoietic agents as neurotherapeutic agents: what barriers exist? Oncology 2002;16:S91–S107.
Grasso G, Buemi M, Alafaci C et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subrachnoid hemorrhage. Proc Natl Acad Sci USA 2002;99:5627–5631.
Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med 2002;8:495–505.
Katavetin P, Tungsanga K, Eiam-Ong S et al. Antioxidative effects of erythropoietin. Kidney Internat 2007;72:S10–S15.
Veng-Pedersen P, Widness JA, Pereira LM et al. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis: application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995;84:760–767.
Widness JA, Veng-Pedersen P, Peters C et al. Erythropoietin pharmacokinetics in premature infants: developmental nonlinearity, treatment effects. J Appl Physiol 1996;80:140–148.
Veng-Pedersen P, Widness JA, Pereira LM et al. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999;20:217–223.
Kato M, Kamiyama H, Okazaki A et al. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997;283:520–527.
Stohlman F. Observations on the physiology of erythropoietin and its role in the regulation of red cell production. Ann NY Acad Sci 1959;77:710–724.
Jelkmann W, Wiedemann G. Serum erythropoietin, level: relationships to blood hemoglobin concentration erythrocytic activity of the bone marrow. Klin Wochensch 1990;68:403–407.
Davies SV, Fegan CD, Kendall R et al. Serum erythropoietin during autologous bone marrow transplantion: relationship to measures of erythroid activity. Clin Lab Haematol 1995;17:139–144.
Grace RJ, Kendall RG, Hartley AE et al. Changes in serum erythropoietin levels during allogeneic bone marrow transplantation. Eur J Haematol 1991;47:81–85.
Pavolovic-Kentera V, Milenkovic P, Ruvidic R et al. Erythropoietin in aplastic anemia. Blut 1979;39:345–350.
Hammond D, Shore N, Movassaghi N. Production utilization excretion of erythropoietin. I. Chronic anemias. II. Aplastic crisis. III. Erythropoietic effects of normal plasma. Ann NY Acad Sci 1968;149:516–527.
de Klerk G, Rosengarten P, Vet R et al. Serum erythropoietin titers in anemia Blood 1981; 58:1164–1170.
Alexanian R. Erythropoietin excretion in bone marrow failure and hemolytic anemia. J Lab Clin Med 1973;82:438–445.
Beguin Y, Clemons GK, Pootrakul P et al. Quantitative assessment of erythropoiesis functional classification of anemia based on measurements of serum transferrin receptor erythropoietin: Blood 1993;81:1067–1076.
Embury SH, Garcia JF, Mohandas N et al. Effects of oxygen inhalation on endogenous erythropoietin, kinetics erythropoiesis properties of blood cells in sickle-cell anemia. N Engl J Med 1984;311:291–295.
Eckard KU, Dittmer J, Neumann R et al. Decline of erythropoietin formation at continuous hypoxia is not due to feedback inhibition. Am J Physiol 1990;258:F1432–F1437.
Kinoshita H, Ohishi N, Kato M et al. Pharmacokinetics distribution of recombinant erythropoietin in rats. Drug Res 1992;42:174–178.
Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989;73:90–99.
Kato M, Kato Y, Sugiyama Y. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. Am J Physiol Endocrinol Metab 1999;276:E887–E895.
Chapel S, Veng-Pedersen P, Hohl RJ et al. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001;298:820–824.
Walrafen P, Verdier F, Kadri Z et al. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005;105:600–608.
Widness JA, Schmidt RL, Hohl RJ et al. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther 2007;81:873–879.
Heatherington AC, Dittrich C, Sullivan JT et al. Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. Clin Pharmacokinet 2006;45:199–211.
Piroso E, Erslev A, Flaharty K et al. Erythropoietin life span in rats with hypoplastic hyperplastic bone marrows. Am J Hematol 1991;36:105–110.
Agoram B, Molineux G, Jang G et al. Effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: a minir role of erythropoietin receptor-mediated pathways. Nephrol Dial Transplant 2006;21:iv303 [abstract MP013].
Briddell R, Stoney G, Sutherland SG et al. An in vitro investigation of the mode of clearance of erythropoietin by human bone marrow cells. Exp Hematol 2003;31:214 [abstract 46].
Elliott S, Lorenzini T, Chang D et al. Mapping of the active site of recombinant human erythropoietin. Blood 1997;89:493–502.
Yoon WH, Park SJ, Kim IC et al. Pharmacokinetics of recombinant human erythropoietin in rabbits 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 1997;96:227–240.
Schuster SJ, Caro J. Erythropoietin: Physiologic basis for clinical applications. Vox Sang 1993;65:169–179.
Jang G. Darbepoetin alfa (Aranesp) pharmacokinetics is comparable in chronic kidney disease (CKD) patients receiving and not receiving dialysis, in pediatric patients and in healthy adults. Paper presented at: ASN 38th Annual Renal Week Meeting; Philadelphia, PA, 8–13 November 2005.
Fukuda MN, Sasaki H, Lopez L et al. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989;73:84–89.
Nielsen OJ, Egfjord M, Hirth P. The metabolism of recombinant erythropoietin in the isolated perfused rat liver. Liver 1990;10:343–349.
Widness JA, Veng-Pedersen P, Schmidt RL et al. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 1996;279:1205–1210.
Jensen JD, Jensen LW, Madsen JK et al. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 1995;54:111–116.
Elliott S, Egrie J, Browne J et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 2004;32:1146–1155.
Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214–221.
Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:3S–8S.
Harris JM, Martin NE, Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001:40:539–551.
Jolling K, Ruixo JJ, Hemeryck A et al. Population pharmacokinetic analysis of pegylated human erythropoietin in rats. J Pharm Sci 2004;93:3027–3038.
Jolling K, Perez Ruixo JJ, Hemeryck A et al. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005;24:465–475.
Jarsch M, Brandt M, Lanzendörfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63–69.
Veng-Pedersen P, Chapel S, Al-Huniti NH et al. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 2004;25:149–156.
Veng-Pedersen P, Widness JA, Pereira LM et al. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999;20:217–223.
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001;28:507–532.
Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting targetmediated drug disposition. Pharmacol Res 2005;22:1589–1596.
Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetics and pharmacodynamics of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 2007;34:849–868.
Wagner JG. Biopharmaceutics and relevant pharmacokinetics. Hamilton, III., Drug Intelligence Publications, 1971.
Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 1990;66:83–86.
Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in predialysis patients: a double-blind placebo-controlled trial. Ann Intern Med 1989;110:108–114.
Cotes JM, Pippard MJ, Reid CD et al. Characterization of the anemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 1989;70:113–137.
Yamazaki C, Watanabe Y, Sakamoto N. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients. Nippon Jinzo Gakkai Shi 1993;35:1233–1242.
Locatelli F, Reigner B. C.E.R.A. Pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Exp Opin Investig Drugs 2007;16:1649–1661.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Doshi, S., Perez-Ruixo, J.J., Jang, G.R., Chow, A.T. (2009). Pharmacokinetics of erythropoiesis-stimulating agents. In: Elliott, S.G., Foote, M.A., Molineux, G. (eds) Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8698-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8698-6_12
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8694-8
Online ISBN: 978-3-7643-8698-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)